MCID: CPL005
MIFTS: 45

Capillary Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Capillary Disease

MalaCards integrated aliases for Capillary Disease:

Name: Capillary Disease 12 15
Disease of Capillaries 12 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1271
ICD9CM 36 448
SNOMED-CT 69 57223003 58729003
ICD10 34 I78 I78.9
UMLS 74 C0155765

Summaries for Capillary Disease

Disease Ontology : 12 A vascular disease that is located in the capillaries.

MalaCards based summary : Capillary Disease, also known as disease of capillaries, is related to hemangioendothelioma and renal pelvis carcinoma, and has symptoms including petechiae of skin An important gene associated with Capillary Disease is SLC2A1 (Solute Carrier Family 2 Member 1), and among its related pathways/superpathways are PAK Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and endothelial, and related phenotypes are cellular and cardiovascular system

Related Diseases for Capillary Disease

Diseases related to Capillary Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 hemangioendothelioma 10.3 KDR PECAM1
2 renal pelvis carcinoma 10.3 SLC2A1 VEGFA
3 pulmonary vein stenosis 10.3 KDR PECAM1
4 hydrocele 10.3 PECAM1 VEGFA
5 hereditary hemorrhagic telangiectasia 10.2
6 severe nonproliferative diabetic retinopathy 10.2 ALB VEGFA
7 drug-induced lupus erythematosus 10.2 KDR VEGFA
8 acroosteolysis 10.2 ALB VEGFA
9 angiomatous meningioma 10.2 KDR VEGFA
10 background diabetic retinopathy 10.2 ALB VEGFA
11 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 10.2 PECAM1 RASA1 SLC2A1
12 radiation proctitis 10.2 KDR PECAM1 VEGFA
13 hypertensive nephropathy 10.1 ALB VEGFA
14 leukostasis 10.1 KDR VEGFA
15 gastric lymphoma 10.1 ALB VEGFA
16 kidney cancer 10.1 IL2 KDR VEGFA
17 burns 10.1 ALB CSF2
18 pure red-cell aplasia 10.1 ALB IL2
19 mucositis 10.1 CSF2 IL2 VEGFA
20 clear cell renal cell carcinoma 10.1 KDR SLC2A1 VEGFA
21 arteriovenous malformations of the brain 10.1 KDR RASA1 VEGFA
22 coats disease 10.0 KDR VEGFA
23 juvenile nasopharyngeal angiofibroma 10.0 PECAM1 VEGFA
24 cryptococcal meningitis 10.0 CSF2 VEGFA
25 urinary system disease 10.0 ALB IL2 VEGFA
26 intestinal disease 10.0 ALB IL2 VEGFA
27 hydrops, lactic acidosis, and sideroblastic anemia 10.0 ALB SERPING1 VEGFA
28 gastrointestinal system disease 10.0 ALB IL2 VEGFA
29 glomeruloid hemangioma 10.0 FLT1 VEGFA
30 kaposi sarcoma 10.0 CSF2 KDR VEGFA
31 microcystic meningioma 10.0 FLT1 VEGFA
32 ovarian hyperstimulation syndrome 10.0 ALB KDR VEGFA
33 lymphangiosarcoma 10.0 IL2 PROX1 VEGFA
34 buerger disease 10.0
35 median arcuate ligament syndrome 10.0
36 systemic capillary leak syndrome 10.0
37 gastrointestinal system cancer 10.0 ALB KDR VEGFA
38 kaposiform hemangioendothelioma 10.0 KDR PECAM1 PROX1
39 endocrine gland cancer 10.0 ALB KDR VEGFA
40 lipodermatosclerosis 10.0 FLT1 VEGFA
41 capillary leak syndrome 10.0 ALB CSF2 IL2
42 cancer-associated retinopathy 10.0 FLT1 VEGFA
43 lymphangioma 10.0 KDR PROX1 VEGFA
44 acquired immunodeficiency syndrome 10.0 ALB CSF2 IL2
45 nervous system disease 9.9 ALB CSF2 VEGFA
46 placenta accreta 9.9 FLT1 KDR
47 hennekam syndrome 9.9 ALB PROX1
48 hematologic cancer 9.9 CSF2 IL2 KDR VEGFA
49 epithelioid hemangioendothelioma 9.8 FLT1 KDR VEGFA
50 corneal neovascularization 9.8 FLT1 KDR VEGFA

Graphical network of the top 20 diseases related to Capillary Disease:



Diseases related to Capillary Disease

Symptoms & Phenotypes for Capillary Disease

UMLS symptoms related to Capillary Disease:


petechiae of skin

MGI Mouse Phenotypes related to Capillary Disease:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 ALB CSF2 FLT1 IL2 KDR PECAM1
2 cardiovascular system MP:0005385 10.15 CSF2 FLT1 IL2 KDR PECAM1 PROX1
3 homeostasis/metabolism MP:0005376 10.02 ALB CSF2 FLT1 IL2 KDR PECAM1
4 growth/size/body region MP:0005378 10.01 CSF2 FLT1 IL2 KDR PROX1 RASA1
5 digestive/alimentary MP:0005381 9.93 ALB IL2 PECAM1 PROX1 RASA1 VEGFA
6 immune system MP:0005387 9.92 CSF2 FLT1 IL2 KDR PECAM1 PROX1
7 embryo MP:0005380 9.91 CSF2 FLT1 KDR RASA1 SLC2A1 VEGFA
8 mortality/aging MP:0010768 9.81 ALB CSF2 FLT1 IL2 KDR PROX1
9 liver/biliary system MP:0005370 9.73 ALB IL2 KDR PECAM1 PROX1 VEGFA
10 muscle MP:0005369 9.5 ALB FLT1 KDR PECAM1 PROX1 RASA1
11 respiratory system MP:0005388 9.1 CSF2 IL2 KDR PECAM1 PROX1 VEGFA

Drugs & Therapeutics for Capillary Disease

Drugs for Capillary Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
9
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
10
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
11
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
12
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
13
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Bosentan Approved, Investigational Phase 4,Phase 2 147536-97-8 104865
16
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
17
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 3 2068-78-2, 57-22-7 5978
18
Hydroxychloroquine Approved Phase 4 118-42-3 3652
19
Bisoprolol Approved Phase 4 66722-44-9 2405
20
Captopril Approved Phase 4 62571-86-2 44093
21
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
22
Enalaprilat Approved Phase 4 76420-72-9 6917719
23
Eprosartan Approved Phase 4 133040-01-4 5281037
24
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
25
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
26
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
27
Ramipril Approved Phase 4 87333-19-5 5362129
28
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
29
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56330 56329
30
Fosinopril Approved Phase 4 98048-97-6 55891
31
Trandolapril Approved Phase 4 87679-37-6 5484727
32
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
33
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
34
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
35
Spirapril Approved Phase 4 83647-97-6 5311447
36
Losartan Approved Phase 4 114798-26-4 3961
37
Atorvastatin Approved Phase 4,Phase 1,Phase 2 134523-00-5 60823
38
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 7440-70-2 271
39
Caffeic acid Experimental, Investigational Phase 4,Phase 3 331-39-5, 501-16-6 1549111
40
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
41
Candesartan Experimental Phase 4 139481-59-7 2541
42 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
44 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
47 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
48 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
50 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 380)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study Completed NCT00460213 Phase 4 Valsartan 80mg daily;Valsartan 160mg daily
3 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
4 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Completed NCT02480335 Phase 4 bosentan
5 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
6 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
7 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
8 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
9 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
10 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
11 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
12 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
13 NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients Recruiting NCT02817360 Phase 4 RAS-antagonist and beta-blocker up-to maximal dosages
14 Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
15 Atorvastatin in Management of Newly Diagnosed ITP Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
16 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
17 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4 romiplostim
18 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
19 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
20 Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Not yet recruiting NCT03866798 Phase 4
21 Erythropoietin in Hemolytic Uremic Syndrome Not yet recruiting NCT03776851 Phase 4 erythropoietin
22 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
23 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
24 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
25 DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
26 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
27 Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients Unknown status NCT02877212 Phase 3 Eltrombopag
28 A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
29 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Unknown status NCT02270801 Phase 3 rhTPO
30 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
31 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3 rhTPO
32 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
33 Effects of Saxagliptin on Endothelial Function Completed NCT01319357 Phase 3 Saxagliptin;Placebo
34 Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch Completed NCT00275509 Phase 3 Thymoglobulin;Daclizumab;Mycophenolate mofetil;Tacrolimus;Dexamethasone;Prednisone;Cytogam
35 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
36 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
37 Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone Completed NCT02914054 Phase 2, Phase 3 High dose Dexamethasone pulses;Prednisone
38 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3 Caffeic acid;Dexamethasone;Placebo
39 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Completed NCT02553317 Phase 3
40 An Investigation of rhTPO With Different Frequencies in the Management of ITP Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
41 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
42 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3 Prednisone;Dexamethasone
43 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Completed NCT02205541 Phase 3 Eculizumab;Placebo
44 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT02201290 Phase 3 Eltrombopag Tablets;Eltrombopag PfOS
45 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076412 Phase 3 Fostamatinib Disodium;Placebo
46 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076399 Phase 3 Fostamatinib disodium;Placebo
47 Eltrombopag Phase III Study In Chinese Chronic ITP Patients Completed NCT01762761 Phase 3 eltrombopag;placebo
48 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Completed NCT01734044 Phase 3 recombinant human thrombopoietin (rhTPO); dexamethasone;Dexamethasone
49 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Completed NCT01730352 Phase 2, Phase 3 H. pylori triple therapy
50 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) Completed NCT01438840 Phase 3 Avatrombopag;Placebo;Standard of care

Search NIH Clinical Center for Capillary Disease

Genetic Tests for Capillary Disease

Anatomical Context for Capillary Disease

MalaCards organs/tissues related to Capillary Disease:

42
Bone, Kidney, Endothelial, Bone Marrow, Testes, Brain, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Capillary Disease:

20
The Capillaries

Publications for Capillary Disease

Articles related to Capillary Disease:

# Title Authors Year
1
Growth hormone, sorbitol, and diabetic capillary disease. ( 4100908 )
1971
2
Growth hormone, sorbitol, and diabetic capillary disease. ( 4102056 )
1971

Variations for Capillary Disease

Expression for Capillary Disease

Search GEO for disease gene expression data for Capillary Disease.

Pathways for Capillary Disease

Pathways related to Capillary Disease according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 CSF2 FLT1 IL2 KDR SLC2A1
2
Show member pathways
13.01 ALB CSF2 IL2 PECAM1 SERPING1 VEGFA
3 12.54 FLT1 KDR RASA1 VEGFA
4
Show member pathways
12.5 FLT1 KDR RASA1 VEGFA
5
Show member pathways
12.34 CSF2 KDR RASA1 VEGFA
6
Show member pathways
12.18 FLT1 IL2 KDR RASA1
7
Show member pathways
12.04 FLT1 KDR VEGFA
8 11.87 KDR PECAM1 VEGFA
9 11.86 FLT1 KDR VEGFA
10
Show member pathways
11.77 KDR RASA1 VEGFA
11
Show member pathways
11.76 FLT1 KDR VEGFA
12 11.75 ALB KDR PROX1 VEGFA
13 11.67 FLT1 SLC2A1 VEGFA
14 11.61 CSF2 FLT1 VEGFA
15 11.5 FLT1 KDR VEGFA
16
Show member pathways
11.42 FLT1 KDR RASA1 VEGFA
17
Show member pathways
11.41 CSF2 IL2 VEGFA
18 11.27 KDR SERPING1 VEGFA
19 11.21 FLT1 KDR PECAM1 PROX1
20 11.18 FLT1 KDR VEGFA
21 11.15 CSF2 RASA1
22 11.12 IL2 RASA1
23 11.08 CSF2 IL2
24 11.03 FLT1 VEGFA
25 10.89 FLT1 KDR VEGFA
26 10.83 CSF2 FLT1 IL2 KDR
27 10.81 FLT1 KDR VEGFA
28 10.46 FLT1 KDR SLC2A1 VEGFA

GO Terms for Capillary Disease

Cellular components related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ALB CSF2 FLT1 IL2 KDR SERPING1
2 extracellular space GO:0005615 9.5 ALB CSF2 FLT1 IL2 PECAM1 SERPING1
3 blood microparticle GO:0072562 9.43 ALB SERPING1 SLC2A1
4 platelet alpha granule lumen GO:0031093 8.8 ALB SERPING1 VEGFA

Biological processes related to Capillary Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.8 FLT1 KDR PECAM1 VEGFA
2 positive regulation of protein phosphorylation GO:0001934 9.77 IL2 KDR VEGFA
3 positive regulation of angiogenesis GO:0045766 9.74 FLT1 KDR VEGFA
4 regulation of cell shape GO:0008360 9.73 KDR RASA1 VEGFA
5 positive regulation of endothelial cell proliferation GO:0001938 9.69 KDR PROX1 VEGFA
6 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.65 FLT1 KDR VEGFA
7 negative regulation of apoptotic process GO:0043066 9.65 ALB IL2 KDR RASA1 VEGFA
8 vasculogenesis GO:0001570 9.63 KDR RASA1 VEGFA
9 positive regulation of cell proliferation GO:0008284 9.63 CSF2 FLT1 IL2 KDR PROX1 VEGFA
10 platelet degranulation GO:0002576 9.62 ALB PECAM1 SERPING1 VEGFA
11 blood vessel morphogenesis GO:0048514 9.61 FLT1 RASA1
12 peptidyl-tyrosine phosphorylation GO:0018108 9.59 FLT1 KDR
13 positive regulation of focal adhesion assembly GO:0051894 9.58 KDR VEGFA
14 cell migration involved in sprouting angiogenesis GO:0002042 9.58 KDR VEGFA
15 positive regulation of endothelial cell migration GO:0010595 9.58 KDR PROX1 VEGFA
16 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.55 FLT1 VEGFA
17 monocyte differentiation GO:0030224 9.54 CSF2 VEGFA
18 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.54 FLT1 KDR VEGFA
19 positive regulation of positive chemotaxis GO:0050927 9.52 KDR VEGFA
20 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.43 KDR VEGFA
21 vascular endothelial growth factor signaling pathway GO:0038084 9.13 FLT1 KDR VEGFA
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.92 CSF2 IL2 PECAM1 VEGFA

Molecular functions related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 IL2 VEGFA
2 growth factor activity GO:0008083 9.33 CSF2 IL2 VEGFA
3 protein tyrosine kinase activity GO:0004713 8.96 FLT1 KDR
4 vascular endothelial growth factor-activated receptor activity GO:0005021 8.62 FLT1 KDR

Sources for Capillary Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....